Navigation Links
India to Beat Blindness Elimination Target by 2015: Health Minister

Health Minister Anbumani Ramadoss has said that India, home to 12 million blind people, will achieve its blindness elimination// target of 0.3 percent by 2015, five years before the World Health Organisation (WHO) deadline of 2020.

"Currently, blindness prevalence in India is a little above 1.1 percent. And looking at the progress we are making, it would be 0.8 percent by 2010. We are quite sure that the WHO target of 0.3 percent can be achieved by five years before its deadline of 2020," the minister said.

"Cataract is the main reason of blindness in our country and we are conducting more and more camps in both urban and rural areas to deal with it. In 2006, we had conducted 5.2 million cataract surgeries across the country," Ramadoss told IANS in an interview.

A survey put the blind in India at 12 million, out of which 62.6 percent of sightlessness is due to cataract. During 2005, India had witnessed 4.9 million cataract surgeries. Nearly 80 percent of this blind population lives in rural areas.

Ramadoss said the National Programme for Control of Blindness (NPCB) and 'Vision 2020: The Right To Sight' plan have been doing a good job.

"Under these programmes, 70 percent of the money goes to the private sector. Our government is pleased with the results," he said, adding that India is committed to reducing the burden of avoidable blindness.

The minister, however, admitted that India has only 12,000 eye surgeons for a population of over 1 billion, which means one eye surgeon for 100,000 people. In urban areas, there is one eye surgeon for 20,000 people and in rural areas the ratio is one eye surgeon for 250,000 people.

The minister also underlined the need for eye donations. "We need 100,000 eye donations, but receive about 22,000 corneas per year. I have pledged my eyes after death and expect the public to lend its support."

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. AIDS Disaster in India is Imminent
3. Indian Prime Minister has successful Knee Replacement Surgery
4. International community warns India on HIV situation
5. India takes on foot-and-mouth disease by vaccinating animals
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. India to benefit from pharma companies move
8. Healthcare sector is now a multi billion-dollar industry in India
9. The World Bank funds private Hospital in India
10. Parke-Davis (India) runs into rough weather – Court orders attachment of asset
11. Indian Doctor granted US patent on organ regeneration
Post Your Comments:
(Date:5/12/2008)...ONT, Calif., May 12 /PRNewswire/ -- Keck Graduate ...008, commencement ceremony will feature,the gradua...tudent, Eric,Tan, and the unveiling of KGI,s first... of Eric,s achievement in becoming the,first gradu..., KGI,s senior,vice president for academic affairs...
(Date:5/12/2008)... VA Nurses Are ,the Compassionate Heart, of System... The Department of,Veterans Affairs (VA), the nati...ional Nurses Week by honoring six of its top profe...rt of VA,s world-class health care,system," stated... "A great,deal of our reputation comes from the pe...
(Date:5/12/2008)... NASDAQ: CRME TSX: COM, VANCOUVER...Corp.,(NASDAQ: CRME / TSX: COM) today announced th...quarter of 2008 on the afternoon of Tuesday, May 1...and webcast at 4:30pm,Eastern (1:30pm Pacific) on ...onference call, please dial 416-641-6117 or,866-29...
(Date:5/12/2008)...lease is available in French . , Montreal, May...n that the administration of sildenafil protects t... This study was led by Dr. Christine Des Rosiers f...t Institute, in collaboration with Dr. Basil Petro...ty Health Centre (MUHC) and Dr. Christian Deschepp...
Breaking Medicine News(10 mins):Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3
...rley Street plastic surgeon plans to sell a contro...de him and his wife “look years younger”.// He as... his memory and removed wrinkles, and made his wif... enough to be his daughter. The plastic surgeon a...
... respiratory specialists declared yesterday that c...million annually.// Lost of productivity when suf...n, while the health service industry loses ?104mil...itish Thoracic Society (BTS), this figure does not...
...y known as Mandrax, is a "downer" used to get reli...ide effects, however, have led to the banning of t...roduced in the 1960s into the pharmaceutical marke...was also used for other medicinal uses, especially...
... claimed to prevent more sudden deaths than defibr...ted defibrillators according to US scientists.// R... compared such preventive strategies by food suppl...n a computer-simulated community of 100,000 people...
Other Medicine News:Health News:Look younger with HGH!! 2Health News:Delhi Police Seized 4,400 kg of Banned Drug Mandrax 2
(Date:5/8/2008)...IELD, Ill., May 8 /- Siemen...(R) Holdings (LabCorp(R)) today announced,that the...s future,possibilities to co-develop new clinical ...tics, metabolic syndrome, oncology and diabetes. U... on developing new tests that,could make the bigge...
(Date:5/8/2008)...AVEN, Conn., May 8 /- VION ...nced the start of an investigator-sponsored,Phase ...loretazine(R),(VNP40101M) in combination with cyta...ed acute myelogenous leukemia (AML) and high-risk,...g conducted under the,direction of Ellen K. Ritchi...
(Date:5/8/2008)...Data Presentations to Focus on Use of Pro-Healing ...lerate Dual-Antiplatelet Therapy, HONG KONG, May ... both,a randomized pilot study and the real-world ... R stent, the world,s first pro-healing stent, wil... 2008 in Barcelona, Spain., The symposium, titled...
(Date:5/8/2008)...NGTON, Del., May 8 /- Astra...of a supplemental New Drug Application,(sNDA) to t...OQUEL XR(TM),(quetiapine fumarate) Extended-Releas...neralized anxiety disorder (GAD), including mainte...approval has been sought for an,atypical antipsych...
Breaking Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Depression and Alzheimers Risk Linked 16158 1Depression and Alzheimers Risk Linked 16158 2Depression and Alzheimers Risk Linked 16158 3War between the sexes begins before twins birth TAU researchers say 2794 1War between the sexes begins before twins birth TAU researchers say 2794 2U Iowa study finds biological link between pain and fatigue 2792 1U Iowa study finds biological link between pain and fatigue 2792 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 15W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 3
... symptoms of SLE,disease at 52 Weeks and demonstra... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire...nnounced the presentation of Phase 2,trial data de...ficantly reduced disease activity across multiple ... quality of life in,patients with active systemic ...
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
Other Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
...tbeat. The bodys warmth beneath drapes. The life-g...ns are yours to guard, measure, stabilize and cros...roducts helps you do your job, giving you the info... precise management of your patients stability dur...
...aser system used in neurophysiology for studying e...just the amplitude and/or the duration of the stim...laser emission in an ongoing manner by acting on t...r include the high repeatability of the impulses, ...
Medicine Products: